ANGIODYNAMICS INC — Director's Dealing 2021

Jul 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANGIODYNAMICS INC (ANGO)
CIK: 0001275187
Period of Report: 2021-07-14

Reporting Person: Helsel Dave (SVP Global Operations and R&D)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-14	Common Stock	F	640	$26.43	Disposed	18475	Direct
2021-07-17	Common Stock	F	294	$24.76	Disposed	18181	Direct
2021-07-18	Common Stock	F	417	$24.76	Disposed	17764	Direct
2021-07-21	Common Stock	A	4058	—	Acquired	21822	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-21	Performance Right	$	A	8116	Acquired		Common Stock (8116)	Direct
2021-07-21	Non-Qualified Stock Option (right to buy)	$10.27	A	11026	Acquired	2031-07-21	Common Stock (11026)	Direct

Footnotes

F1: The exempt disposition of 640 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 14, 2020.

F2: The exempt disposition of 294 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

F3: The exempt disposition of 417 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

F4: The acquisition of 4,058 shares of Common Stock of the Company represents 4,058 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 21, 2022, such that 25% of the restricted stock units will vest on each of July 21, 2022, 2023, 2024 and 2025.

F5: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F6: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.